S-Nitrosoderivative of a Recombinant Fragment of von Willebrand Factor (S-Nitroso-AR545C) Inhibits Thrombus Formation in Guinea Pig Carotid Artery Thrombosis Model

Summary

Antiplatelet drugs are the mainstays of therapy for acute and chronic cardiovascular diseases. S-nitroso-AR545C – an S-nitrosoderivative of a recombinant von Willebrand factor fragment AR545C spanning Ala 444 to Asp 730 and containing an Arg 545 Cys mutation, was previously found to inhibit ristocetin-and ADP-induced platelet aggregation and the interaction of platelets with extracellular matrix (ECM). In the current study we tested the antithrombotic properties of S-nitroso-AR545C on guinea pig platelets and in a platelet-rich thrombosis model in the guinea pig. Preincubation of guinea pig platelets with 0.1 µM of S-nitroso-AR545C decreased ristocetin-induced agglutination by 40% (p = 0.009) and completely abolished ADP-induced aggregation (p <0.0001). At concentration of 1.0 µM, S-nitroso-AR545C completely inhibited platelet adhesion (represented by surface coverage – SC) and decreased aggregate formation (represented by average aggregate size – AS) by more than 50%. Treatment of guinea pigs with 1.0 mg/kg S-nitroso-AR545C resulted in a significantly delayed time to arterial occlusion (31.7 ± 6.0 min vs. 13.9 ± 3.2 min, p <0.02). Similarly, total patency time was longer in the group injected with S-nitroso-AR545C compared to the control group. However, the difference was not statistically significant (33.8 ± 6.3 min vs. 20.2 ± 3.3 min, p = 0.07). No change in platelet count, hematocrit and bleeding time was observed 60 min after injection compared to baseline. In contrast, a significant decrease in SC (p <0.0001) and AS (p <0.01) were observed 60 min after the injection of S-nitroso-AR545C, whereas no change in these parameters was observed in the control group. These observations indicate that S-nitroso-AR545C exhibits significant antiadhesive and antiaggregating effects in-vitro and inhibits clot formation in-vivo suggesting that this compound may have potential therapeutic advantages.

Key words

von Willebrand factor - platelet inhibitors - nitric oxide

• References

• 1 Alevriadou BR, Moake JL, Turner NA, Ruggeri ZM, Folie BJ, Phillips MD, Schreiber AB, Hrinda ME, Mclntire LV. Real-time analysis of shear-dependent thrombus formation and its blockade by inhibitors of von Willebrand factor binding to platelets. Blood 1993; 81: 1263-76.
• 2 Antiplatelet Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-6.
• 3 Folts JD, Schafer AI, Loscalzo J, Willerson JT, Muller JE. A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with cyclic flow. J Am Coll Cardiol 1999; 33: 295-303.
• 4 Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997; 99: 1467-71.
• 5 Ferguson JJ, Lau TK. New antiplatelet agents for acute coronary syndromes. Am Heart J 1998; 135 (suppl) 194-200.
• 6 Inbal A, Kornbrot N, Harrison P, Randi AM, Sadler JE. Effect of type IIb von Willebrand disease mutation Arg (545) Cys on platelet glycoprotein Ib binding: studies with recombinant von Willebrand factor. Thromb Haemost 1993; 70: 1051-62.
• 7 Gurevitz O, Goldfarb A, Hod H, Feldman M, Shenkman B, Varon D, Eldar M, Inbal A. Recombinant von Willebrand factor fragment AR545C inhibits platelet aggregation and enhances thrombolysis with rtPA in a rabbit thrombosis model. Arteriosclerosis, Thrombosis and Vascular Biology 1998; 18: 200-7.
• 8 Inbal A, Gurevitz O, Eskaraev R, Feldman M, Varon D, Tamarin I, Eldar M, Loscalzo J. Unique antiplatelet effects of a novel S-nitrosoderivative of a recombinant fragment of von Willebrand factor, AR545C: in vitro and ex vivo inhibition of platelet function. Blood 1999; 94: 1693-700.
• 9 Saville B. A scheme for the colorimetric determination of microgram amounts of thiols. Analyst (Lond) 1958; 83: 670.
• 10 Varon D, Dardik R, Shenkman B, Kotev-Emeth S, Farzame N, Tamarin I, Savion N. A new method for quantitative analysis of whole blood and platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997; 85: 283-94.
• 11 Varon D, Lasherski I, Brenner B, Beyar R, Lanir N, Tamarin I, Savion N. Cone and plate(let) analyser: monitoring glycoprotein IIb/IIIa antagonists and von Willebrand disease replacement therapy by testing platelet deposition under flow conditions. Am Heart J 1998; 135: S187-S93.
• 12 Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-80.
• 13 Kupinski JM, Miller JL. Synthesis by guinea pig megakariocytes of platelet glycoprotein receptors for fibrinogen and von Willebrand factor. Thromb Res 1986; 43: 345-52.
• 14 Ashton JH, Benedict CR, Fitzgerald C, Raheja S, Taylor A, Campbell WB, Buja LM, Willerson JT. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986; 73: 572-8.
• 15 Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Cullere M, Hynes RO, Wagner DD. A mouse model of severe von Willebrand disease: Defects in hemostasis and thrombosis. Proc Natl Acad Sci, USA 1998; 95: 9524-9.
• 16 Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 1999; 93: 1825-30.
• 17 Azzam K, Garfinkel LI, Bal Cdit-Sollier, Cisse MThiam, Drouet L. Antithrombotic effect of a recombinant von Willebrand factor, VCL, on nitrogen laser-induced thrombus formation in guinea pig mesenteric arteries. Thromb Haemost 1995; 73: 318-23.
• 18 Guth BD, Seewaldt-Becker E, Himmelsbach F, Weisenberger H, Muller TH. Antagonism of the GPIIbIIIa receptor with the nonpeptidic molecule BIBU52: Inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo. J Cardiovasc Pharmacol 1997; 30: 261-72.
• 19 Kawamura M, Tsuji N, Moriya N, Terashita Z. Effects of TAK-029, a novel GPIIbIIIa antagonist, on arterial thrombosis in guinea pigs, dogs and monkeys. Thromb Res 1997; 86: 275-85.
• 20 Myers PR, Minor RL, Guerra Jr R, Bates JN, Harrison DG. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrocysteine than nitric oxide. Nature 1990; 345: 161-3.
• 21 Nakashima S, Toyohiko T, Hattori H, Okano Y, Nozawa Y. Inhibitory action of cyclic GMP on secretion, polyphosphoinositide hydrolysis and calcium mobilization in thrombin-stimulated human platelet. Biochem Biophys Res Commun 1986; 135: 1099-104.
• 22 Stamler JS, Loscalzo J. The antiplatelet effects of organic nitrates and related nitroso-compounds in vitro and in vivo and their relevance to cardiovascular disorders. J Am Coll Cardiol 1991; 18: 1529-36.
• 23 Folts JD, Stamler JS, Loscalzo J. Intravenous nitroglycerine infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed canine coronary arteries. Circulation 1991; 83: 2122-7.
• 24 Rovin JD, Stamler JS, Loscalzo J, Folts JD. Sodium nitroprusside, an endothelium-derived relaxing factor congener, increases platelet cyclic GMP levels and inhibits epinephrine exacerbated in vivo platelet thrombus formation in stenosed canine coronary arteries. J Cardiovasc Pharmac 1993; 22: 626-33.
• 25 Korbut R, Lidbury PS, Vane JR. Prolongation of fibrinolytic activity of tissue plasminogen activator by nitrosodilators. Lancet 1990; 335: 669.
• 26 Garg UC, Hassid A. Nitric oxide generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-7.
• 27 McNamara DB, Bedi B, Aurora H, Tena L, Ignarro LJ, Kadowitz PJ, Akers DL. L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun 1993; 193: 291-6.
• 28 Hamon M, Vallet B, Bauters C, Wernert N, McFadden EP, Lablanche JM, Dupius B, Bertrand ME. Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation 1994; 90: 1357-62.
• 29 Tarry WC, Malhoul RG. L-arginine improves endothelium-dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty. Arterioscler Thromb 1994; 14: 938-43.
• 30 Guo J, Milhoan KA, Tuan RS, Lefer AM. Beneficial effect of SPM-5185, a cysteine-containing nitric oxide donor in rat carotid artery intimal injury. Circ Res 1994; 75: 77-84.
• 31 Seki J, Nishio M, Kato Y, Motoyama Y, Yoshida K. FK 409, a new nitricoxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty. Atherosclerosis 1995; 117: 97-106.
• 32 Lee JS, Adrie C, Jacob HJ, Roberts Jr. JD, Zapol WM, Bloch KD. Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury. Circ Res 1996; 78: 337-42.
• 33 Sasaki Y, Seki J, Giddings JC, Yamamoto J. Effects of NO donors on thrombus formation and microcirculation in cerebral vessels of the rat. Thromb Haemost 1996; 76: 111-7.
• 34 Lechi C, Andrioli G, Gaino S, Tommasoli R, Zuliani V, Ortolani R, Degan M, Benoni G, Bellavite P, Lechi A, Minuz P. The antiplatelet effects of a new nitroderivative of acetylsalicylic acid. An in vivo study of inhibition on the early phase of platelet activation and on TxA₂ production. Thromb Haemost 1996; 76: 791-8.
• 35 Hirasawa Y, Kato Y, Fukuyama S, Ohno M, Nishino S, Kato M, Kita Y. Comparison of antiplatelet effects of two nitric oxide donating agents. FR146801 and FK 409. Thromb Haemost 1998; 79: 620-4.